The Centers for Disease Control and Prevention and the American Congress of Obstetricians and Gynecologists recommend universal prenatal HIV testing to prevent perinatal HIV transmission in the U.S.; since the 1990s perinatal HIV transmission has declined. In 2006, 74% of women with a recent live birth reported testing for HIV prenatally or at delivery. We used Pregnancy Risk Assessment Monitoring System data from 36 states and New York City from 2004 to 2013 (N ¼ 387,424) to assess characteristics associated with lack of self-reported testing and state-to-state variability in these associations. Overall, 75.2% (95% confidence interval [CI] 75.0-75.5) of women with a recent live birth reported an HIV test. There were significant differences in testing prevalence by state, ranging from 91.8% (95% CI 91.0-92.6) in New York to 42.3% (95% CI 41.7-43.5) in Utah. In adjusted analysis, characteristics associated with no reported testing included being married, white, non-Hispanic, multiparous, not smoking during pregnancy, and having neither Medicaid nor Special Supplemental Nutritional Program for Women, Infants, and Children. White married women were 57% (adjusted prevalence ratio [aPR] 1.57, 95% CI 1.52-1.63) more likely to report no test compared to white unmarried women. Multiparous married women were 57% (aPR 1.57, 95% CI 1.51-1.64) more likely to report no test compared to multiparous unmarried women. Women who were married, white, non-Hispanic, and multiparous women were 23% less likely to be tested than other women combined. Marital status was significantly associated with lower prevalence of testing in 35 of the 37 reporting areas, and race was significant in 30 of 35 states with race information. The prevalence of reported HIV testing during pregnancy or at delivery remains below 80%. Opportunities exist to increase HIV testing among pregnant women, particularly among certain subpopulations.
Introduction
Although HIV transmission in the U.S. remains a public health concern, HIV transmission from mothers to infants during pregnancy, delivery, or postpartum is now rare. 1, 2 Since the late 1990s, perinatal HIV acquisition has been reduced 96%, to 1.75/100,000 in 2013. 2 Through advances in pharmaceutical and clinical research, guidelines development, and changes to clinical practice, the number of HIV-infected children born in the U.S. decreased from an estimate of 1650 in 1991 to 69 in 2013, and perinatal transmission rates decreased from 35% to less than 3%. 1, 2 Five steps in clinical care contribute to reduce perinatal transmission; the first is the diagnosis of maternal HIV infection, which evolved from a counseling and testing approach to an 'opt-out' approach at prenatal care intake, or at delivery for those with undocumented HIV testing during pregnancy. 3, 4 The second involves provision of antiretroviral therapy for all HIV-infected pregnant women through pregnancy, delivery, and postpartum; third is consideration of cesarean delivery; fourth is alternatives to maternal breastfeeding; 5 fifth is infant antiretroviral prophylaxis. 6 The Centers for Disease Control and Prevention (CDC) and the American Congress of Obstetricians and Gynecologists (ACOG) now recommend universal HIV testing early during pregnancy, a second test in the third trimester for women at high risk, and testing at labor and delivery for those with undocumented HIV status. [3] [4] [5] Testing is critical to prevention since it allows for consideration and implementation of the five steps above; 6 these five can reduce the risk of motherto-child transmission to less than 1%. 7 However, although state laws and national guidelines and recommendations support universal HIV testing during each pregnancy, [3] [4] [5] and testing is cost effective even at very low prevalence, 8 not all women receive a test. 9, 10 A companion paper 11 using the Pregnancy Risk Assessment Monitoring System (PRAMS) examined trends in self-reported HIV testing rates from 2004 to 2011 (the most current available) in relation to state policies and found little to no change in the testing rate over time. We used PRAMS data from 2004 to 2013 to assess whether characteristics differed between tested women and not tested women, nationally and by state, in order to inform policy-makers and clinicians about opportunities to increase communication and testing.
Methods
PRAMS is an ongoing population-based surveillance collaboration between CDC and state health departments that identifies and monitors selected maternal experiences, behaviors, and conditions before, during, and after pregnancy.
12 During each annual surveillance period during 2004-2013, PRAMS surveyed a sample of postpartum women who delivered a live-born infant; in 2013, the survey was being administered in 36 participating states and New York City. Our sample represents approximately 70% of all live births in the United States during this period 13, 14 (Appendix A in online supplemental files).
A state's birth certificate file serves as the sampling frame; each state uses the same standardized mailtelephone methodology. Between two and four months following delivery, surveys are sent by mail to the birth mother; mail nonrespondents are contacted via telephone. PRAMS-participating state health departments select and employ state-specific stratification schemes, oversampling subpopulations of particular public health interest, such as mothers of low birthweight infants and racial/ethnic minority groups. Annual sample sizes vary by state (see Appendix A in online supplemental files), with larger sample sizes for larger states or those with more complex stratification schemes. 14, 15 In each state, self-reported survey data are linked to birth certificate data for each year and weighted for sample design, nonresponse, and noncoverage to be representative of all women who gave birth to a live-born infant. Detailed information about the PRAMS methodology is available (http:// www.cdc.gov/prams/methodology.htm). The CDC and local Institutional Review Boards approved the PRAMS protocol and use of deidentified data by investigators for secondary analyses.
PRAMS requires that published data meet or exceed minimum weighted response rates of 70% for years [2004] [2005] [2006] , 65% for years 2007-2011, and 60% for 2012 and 2013. We used PRAMS data from 36 states and New York City (hereafter referred to as 'states') meeting these criteria, combining the years 2004-2013, representing 70% of live births (see Appendix A and Appendix B in online supplemental files). All participating PRAMS sites approved this analysis.
Variables
Pregnancy-related characteristics explored were based on previous literature. 9, 10 Data on maternal demographic characteristics (maternal age, education, race, ethnicity, and marital status) were derived from the birth certificate, while pregnancy intention; parity; income; enrollment in the Special Supplemental Nutritional Program for Women, Infants, and Children (WIC) and Medicaid; smoking status during last trimester; alcohol use (before and during pregnancy); length of delivery hospital stay; physical abuse; hospitalization during pregnancy; and prenatal care visits (onset, number) were based on self-report from the PRAMS questionnaire. Since income data are collected by states for local purposes, the income categories used by states do not always match; we used the following categories and fit states' data as appropriate into the closest fitting category: $0-$15,000, $15,000-$50,000, or greater than $50,000.
Since 16 classified maternal education based on years of school completed, and pregnancy intention using the following question, 'Thinking back to just before you got pregnant with your new baby, how did you feel about becoming pregnant?' Women who answered that they wanted their pregnancy 'sooner' or 'then' were classified as having an intended pregnancy, and those who answered 'later,' 'did not want,' or 'did not want at any time' were classified as having an unintended pregnancy.
Outcome
Women were asked if they had received a test for HIV during prenatal care visits or at delivery. For this analysis, we used this question 'At any time during your most recent pregnancy or delivery, did you have a test for HIV (the virus that causes AIDS)?' Respondents who answered 'yes' or 'no' were included in the analysis.
Analysis
Sample weights were used in all analyses to account for unequal probability of selection. SAS-callable SUDAAN (RTI International, Research Triangle Park, NC) was used to account for the stratified complex survey design; we present weighted estimates. We used Chi square tests to examine differences in distribution of characteristics between women tested and not tested for HIV. We performed multivariable analyses with main effects in bivariate analyses with P < 0.15. Nonsignificant effects were removed stepwise from the model; this was repeated until a parsimonious model with all significant effects at P < 0.001 was observed. Because the national sample was very large, the overall final multivariable logistic regression model included main effects, then main effects variables were examined for two-way interactions; terms of p < 0.001 were retained. Because more than 10% of women reported no HIV test during pregnancy or at delivery, for the national analysis we calculated adjusted prevalence ratios (aPRs) by using predicted marginals from logistic regression models and then converting these estimates to prevalence ratios. 17 
Results
A total of 37 PRAMS states reported one or more years of data during 2004-2013, for a total unweighted sample size of 387,424. Appendix A and Appendix B in the online supplemental files include yearly statespecific sample sizes and response rates.
On reporting of an HIV test, 334,166 (86%) responded 'yes' or 'no' and were included. Among included women, 53.4% (for 95% confidence interval [CI] see Table 1 ) were aged 25-34 years, 70.9% were white, 16.9% were Hispanic, 60.9% were married, 29.2% made less than $15,000 per year, 42.0% had delivered their first child, 58.8% had intended pregnancies, 11.5% smoked in their last trimester, 36.8% received both Medicaid and WIC, 66.8% reported adequate prenatal care (Table 1 ). In addition, 89.2% (95% CI 89.1-89.4) were hospitalized for four days or less for delivery, 55.6% (95% CI 55.4-56.0) had more than 12 years of education, 52.2% (95% CI 52.0-52.5) drank alcohol three months before pregnancy, 7.0% (95% CI 6.9-7.2) drank in the last three months of pregnancy, and 4.5% (95% CI 4.3-4.6) were physically abused before pregnancy.
Overall, 75.2% (95% CI 75.0-75. 
Discussion
Among women with a recent live birth who participated in PRAMS during 2004-2013, the overall rate of HIV testing during pregnancy or at delivery was 75%, which is similar to the rate found in 2006, 9 similar to two smaller analyses using claims data from 2007 (62%) and 2008 (74.1%) that also examined syphilis testing, 18, 19 and similar annually to the year-by-year analysis of 2004-2011 PRAMS data in a companion article. 11 There has been no appreciable change since 3, 5 We found differences in testing rates during pregnancy or delivery among certain subpopulations of women. Married, multiparous, white, non-Hispanic women were less likely to report testing than their counterparts; we found significant interactions between several of these variables, which may not have been elucidated in studies with smaller sample sizes. The characteristics associated with self-report of nonreceipt of an HIV test included marital status, race, Hispanic ethnicity, Medicaid/WIC status, parity, and smoking in the last trimester of pregnancy. In comparison, in 2005-2006, medical records from 4762 pregnant women were reviewed for documentation of HIV testing; 74% had evidence of testing before delivery. Women who did not have documentation of testing were more likely to be non-Hispanic, white, and use non-Medicaid insurance, 9 similar to our findings. Characteristics we identified as significant on bivariate analysis are consistent with another study. 10 An analysis of 2002 NSFG data found an overall reported testing rate during prenatal care of 69%; women less likely to report an HIV test were those reporting higher (versus lower) income and those with some college education (versus not completing high school). 10 The study's small sample size of 768 women, however, may have limited the ability to assess multiple characteristics and interactions. Education and income, while significant in univariate analysis, dropped from our multivariate model.
Compared to all other women in the sample, women who were married, white, non-Hispanic, and multiparous were 23% less likely to report testing. Providers may consider married, white, and non-Medicaid or WIC-receiving women to be at low risk for HIV. However, the emergence of local HIV transmission, including to pregnant women, associated with parenteral opioid drug use in a predominantly rural, white county in Indiana indicates that undetected transmission may be occurring among women considered 'low risk.' 20 The reasons for the lower testing rate among married, white, non-Hispanic, and multiparous women are unclear but may involve differences in individual or health care systems approaches to prenatal care: biases by providers or care systems, and policies differentially applied or implemented. Research to describe factors leading to no testing among different groups of women, even those who reported higher rates, may provide insight into potential interventions to improve testing rates.
The Healthy People 2020 target for HIV prenatal testing is 79.5%. 21 Our analysis indicates that testing rates are near this target (75.3%). CDC estimated that there were still more than 8000 women of reproductive age who were diagnosed with HIV infection in 2014. 2 Because U.S. women and their infants continue to become infected with HIV, efforts are needed to increase testing, especially in the populations we identified as having low testing coverage. HIV testing is cost effective (savings are greater than costs) at a rate of 7.5/100,000 or one out of 13,333 pregnant women. 8 Previous publications suggest the 'opt-out' approach, in which all women are tested unless they specifically opt out of testing, could maximize routine screening to provide universal HIV testing. This approach limits the need for lengthy counseling and may improve testing rates despite lingering stigma. 5, 22 Fitz Harris et al. analyzed PRAMS data by year (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) and assessed the effect of state policies or laws in the last ten years to improve testing. They found that areas where testing rates have increased implemented policy changes, passed laws, or worked with providers on quality initiatives that may have led to increased testing. 11 Areas where HIV testing has remained stable or decreased may benefit from implementing successful activities.
Because PRAMS data are self-reported and women may be screened as part of routine prenatal care on an opt-out basis, some women may not know that they have been tested for HIV, particularly if health care providers do not discuss negative test results. Therefore, this analysis may underestimate actual testing. PRAMS does not ask about repeat testing during pregnancy (or about infant testing), so we could not assess adherence to the repeat testing recommendation. The sensitivity and specificity of the PRAMS HIV testing question was examined by comparing PRAMS data to medical records in New York City and Vermont in 2009. 23 The authors found that the sensitivity (women who reported testing to PRAMS, of all women tested) was 89.6 and 67.7%, the specificity (women reporting no testing to PRAMS, of all women not tested) 14.7 and 61.6%, and the positive predictive value 98.3 and 90.8% in NYC and Vermont, respectively. We only analyzed the 'yes' responses to indicate testing and did not analyze the 'no' responses. Based on the published sensitivity, we likely underestimate the true prevalence of HIV testing during pregnancy or at delivery. If a correction from NY and VT were applied to other states, the testing rate reported here would be estimated at between 84 and 100%. However, testing rates using claims data found similar results to this analysis. 18, 19 Other limitations include the respondents' missing income data (n ¼ 36,146), that not all states reported race, and that we did not assess subgroup trends by state. However, consistently significant differences among characteristics of women reporting HIV testing across states suggest that testing is not uniform.
Women may decline testing if they recall that they have been tested in the recent past. 24 Current recommendations state that women at high risk for HIV should be tested twice during pregnancy. 4 ,5 PRAMS does not distinguish between prenatal or delivery testing, nor assess whether high-risk women are getting a second test in the third trimester, as is currently recommended.
These data represent 36 states and one city; notably, because of low response rates, several southern states participating in PRAMS did not contribute data or did not contribute each year (see Appendix A in online supplemental files). While 2002 data from NSFG found higher testing rates in southern states, 10 yearto-year variations in state-specific testing rates from 2004 to 2011 are available and southern states had lower testing rates in more recent years. 11 Inclusion of data from these states might have lowered the estimate. Despite these limitations, our data suggest that improvements in HIV testing coverage are possible, particularly among subpopulations often considered low risk and certain states.
In summary, in this PRAMS analysis, we found that during 2004-2013, one out of every four women with a recent live birth reported not being tested for HIV during pregnancy or at delivery. The testing rate has not changed substantially in the last ten years. 11 HIV testing is cost effective and universal testing is recommended by ACOG and CDC; local efforts to implement universal HIV testing may reduce differences in testing rates between subpopulations and further reduce perinatal transmission.
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